NICE Wants More Evidence To Clear Janssen’s Velcade For Multiple Myeloma
This article was originally published in The Pink Sheet Daily
The British HTA NICE wants more clinical and cost-effectiveness data on Janssen’s Velcade in combination therapy before clearing it for battle with thalidomide for multiple myeloma.
You may also be interested in...
Velcade Remains Second To Thalidomide in NICE's Multiple Myeloma Appraisal; Janssen Not To Appeal This Time
Janssen gains access to confidential data following a favorable ruling by NICE's Appeal Board, but Celgene's thalidomide is still preferred to Janssen's bortezomib in multiple myeloma.
Janssen's Velcade and Celgene's thalidomide both recommended as first-line multiple myeloma therapies, but thalidomide is more cost-effective, says NICE's final appraisal determination.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.